Quarterly Activities/Appendix 4C Cash Flow Report
| Stock | HYDRIX Ltd (HYD.ASX) |
|---|---|
| Release Time | 30 Jan 2026, 3:28 p.m. |
| Price Sensitive | Yes |
Hydrix Releases Quarterly Activities/Appendix 4C Cash Flow Report
- $2.3m in revenues for the quarter from international cardiac and medtech clients, plus Australian defence & industrial clients
- Announced a $2.5m initial contract stage with SynCardia Systems to collaborate on the development of a fully implantable total artificial heart
- Hydrix Medical progressing sales opportunities of its remote cardiac monitoring software
Hydrix Limited (ASX: HYD) has released its Appendix 4C for the quarter ended 31 December 2025 and provided a market update. Key highlights include $2.3m in revenues for the quarter, primarily from international cardiac and medtech product clients plus Australian defence & industrial clients. The company announced a $2.5m initial contract stage with SynCardia Systems, Inc to collaborate on the development of SynCardia's fully implantable total artificial heart, the Emperor. Hydrix Medical is progressing sales opportunities of its remote cardiac monitoring software, while Hydrix Venture company Gyder Surgical has progressed towards first-in-human use cases in the USA and commenced a capital raise to support USA market expansion. The company reported a $0.71m cash operating loss, which was primarily funded from positive working capital movements, with $0.6m cash on hand further supported by a $2.5m Letter of Comfort from two Directors. Hydrix Executive Chairman, Gavin Coote, commented that the new contract with SynCardia combined with other current sales opportunities underpin a stronger outlook for CY2026 in terms of revenues and cash flows.
Hydrix announced a new $2.5m initial contract stage with SynCardia Systems, Inc to collaborate on the development of SynCardia's fully implantable total artificial heart, the Emperor. This multi-year, multi-million-dollar project is expected to contribute to stronger revenues and cash flows for the company in the 2026 calendar year.
The company sees several opportunities to grow the business and unlock shareholder value, with the new contract with SynCardia and other current sales opportunities underpinning a stronger outlook for CY2026 in terms of revenues and cash flows.